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Abstract
The coronary vasculature is an essential vessel network providing the blood supply to the
heart. Disruptions in coronary blood flow contribute to cardiac disease, a major cause of pre-
mature death worldwide. The generation of treatments for cardiovascular disease will be
aided by a deeper understanding of the developmental processes that underpin coronary
vessel formation. From an ENU mutagenesis screen, we have isolated a mouse mutant dis-
playing embryonic hydrocephalus and cardiac defects (EHC). Positional cloning and candi-
date gene analysis revealed that the EHC phenotype results from a point mutation in a
splice donor site of the Myh10 gene, which encodes NMHC IIB. Complementation testing
confirmed that the Myh10 mutation causes the EHC phenotype. Characterisation of the
EHC cardiac defects revealed abnormalities in myocardial development, consistent with
observations from previously generated NMHC IIB null mouse lines. Analysis of the EHC
mutant hearts also identified defects in the formation of the coronary vasculature. We attri-
bute the coronary vessel abnormalities to defective epicardial cell function, as the EHC epi-
cardium displays an abnormal cell morphology, reduced capacity to undergo epithelial-
mesenchymal transition (EMT), and impaired migration of epicardial-derived cells (EPDCs)
into the myocardium. Our studies on the EHC mutant demonstrate a requirement for NMHC
IIB in epicardial function and coronary vessel formation, highlighting the importance of this
protein in cardiac development and ultimately, embryonic survival.
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Author summary
In order for the heart to function properly it must have its own blood supply. Blood is
delivered to the heart through a system of vessels called the coronary vasculature. During
development, some of the cells that form the coronary vessels originate from the epicar-
dium, the outer layer of the heart. These epicardial-derived cells migrate into the cardiac
tissue where they contribute to the formation of the coronary vascular network. We have
found that a mouse mutant containing a mutation in the gene Myh10, which encodes the
cytoskeletal protein non-muscle myosin IIB, fails to form the coronary vasculature. Our
work reveals defects in the epicardium, which contribute to the lack of coronary vessel
development in this mutant. Surprisingly, we discovered that whilst the mutant epicardial
cells are capable of movement when extracted from the embryo, these cells fail to mobilise
into a vascular network in the context of the developing embryonic heart. We propose
that this migration failure is due to abnormalities in the extracellular environment in the
mutant heart. This work highlights the importance of the Myh10 gene in the critical devel-
opmental process of coronary vessel formation.
Introduction
A functional coronary vasculature is essential to supply the heart with oxygenated blood. Ces-
sation of the coronary circulation deprives the working myocardium of oxygen and nutrients,
leading to irreversible damage to cardiac muscle and myocardial infarction. Coronary artery
disease is the main form of cardiovascular disease, and causes significant morbidity and mortal-
ity world-wide [1]. Although mammals and other higher vertebrates have insufficient capacity
to restore cardiac function following ischemia, a number of studies that exogenously reactivate
elements of embryonic coronary vessel formation have demonstrated neovascularisation and
regeneration of the infarcted mouse heart, consequently improving cardiac function [2–5].
Moreover, experiments using thymosin β4 have revealed that the specific restoration of the qui-
escent adult epicardium, the outer epithelial layer of the heart, to an embryonic state, permits
the activation of cardiac precursors that contribute to neovascularisation in vitro [6] and in vivo
[2, 7]. However, our comprehension of both the cellular and molecular mechanisms that con-
trol this regeneration remain incomplete. Therefore, a deeper understanding of the processes
that underpin coronary vessel formation may facilitate the generation of advanced and novel
therapies to repair the injured heart.
During mammalian cardiac development cells from the proepicardial organ (PEO) migrate
onto the surface of the heart and adhere to the nascent myocardium of the post-looped heart
tube [8]. This gives rise to an outer epithelial layer, termed the epicardium, which completely
envelops the developing heart. Epicardial function is critical for cardiac development, since the
epicardium provides a source of paracrine signals for myocardial growth (reviewed in [9–11]).
Additionally, as cardiac development progresses, a subset of epicardial cells undergo EMT and
migrate through the subepicardial space to contribute to the formation of the coronary vascu-
lature and cardiac fibroblasts (reviewed in [11–15]). While the contribution of the epicardium
to the endothelial cell lining of the coronary vessels has been challenged recently [15, 16], it is
clear that epicardial function is absolutely essential to establish the coronary vasculature and
facilitate cardiogenesis. Furthermore, reactivating embryonic processes in the quiescent adult
epicardium has been shown to facilitate the repair and regeneration of cardiac tissue in
response to injury, highlighting the therapeutic potential of this tissue [5, 17, 18].
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A comprehensive understanding of the critical molecular mechanisms that underpin
epicardial function during mammalian cardiogenesis is needed to facilitate the development of
epicardial-based therapies. To this end, we have studied mouse mutants with cardiac defects
isolated from a balancer chromosome mutagenesis screen. We found that the l11Jus27 mutant
[19] carried two different embryonic lethal mutations, one of which displayed a phenotype of
embryonic hydrocephalus and cardiac defects (EHC). EHC mutant embryos fail to form a
mature, functional coronary system, resulting in late-gestation lethality. We identified a muta-
tion in a splice-donor site in the Myh10 gene as the cause of the EHC phenotype. Myh10
encodes Non-Muscle Myosin Heavy Chain IIB (NMHC IIB), a component of the protein hex-
amer Non-Muscle Myosin IIB (NMIIB). There are 3 different NMHC II isoforms (namely IIA,
IIB and IIC), each displaying specific cellular expression and functionality (reviewed exten-
sively in [20, 21]). NMHC IIB is a cytoskeletal protein with diverse functions, including: cyto-
kinesis [22, 23], regulation of cell shape [24], adhesion [25, 26] and migration [27, 28]. Prior
studies of other mutants with abnormal coronary vessel development have shown that these
defects arise primarily from epicardial cell dysfunction [29–32]. Accordingly, EHC mutant
epicardial cells form an abnormal epithelial layer on the surface of the heart. In addition, the
migration of EHC epicardial-derived cells into the underlying myocardium is impaired. EHC
epicardial cells also show decreased expression of EMT markers within the epicardium, sug-
gesting that NMHC IIB not only plays an important role in regulating EPDC migration, but
also in promoting epicardial EMT. Ultimately, NMHC IIB may therefore function in multiple
processes during coronary vessel formation and cardiogenesis, which could potentially be
manipulated to repair and regenerate the heart in the context of cardiovascular disease.
Results
Isolation of the EHC mutant
A study of ENU (N-ethyl-N-nitrosourea) mutagenised mouse strains with embryonic lethal
recessive mutations revealed that homozygous mutant embryos from the l11Jus27 mouse line
displayed enlarged, distended hearts with oedema [19]. A meiotic mapping approach was
employed to further refine the l11Jus27 candidate region. Animals with recombination events
within the balancer chromosome interval were test-crossed to known l11Jus27 carriers, and
viable offspring were genotyped for several markers in the balancer chromosome region. Cor-
relations between the inheritance of C57BL/6 genomic DNA (mutagenised strain) and the
l11Jus27 phenotype (early embryonic lethality) were evaluated. The failure of a recombinant
animal crossed to a known l11Jus27 carrier to produce homozygous C57BL/6 offspring would
suggest that the homozygous C57BL/6 embryos died in utero, consistent with the l11Jus27 phe-
notype. This finding would indicate that the l11Jus27 mutation is located in the genomic
region where the recombinant animal has inherited C57BL/6 DNA. Unexpectedly, two recom-
binant mice failed to produce homozygous C57BL/6 viable offspring when mated to known
l11Jus27 heterozygotes (Fig 1A). Both of these animals carried C57BL/6 DNA in non-overlap-
ping sub-regions of the balancer interval, suggesting that they could not carry the same embry-
onic lethal mutation. Recombinant 363 carried C57BL/6 genomic DNA in a 4.1Mb region
extending beyond the Trp53 endpoint of the balancer chromosome, and recombinant 508 car-
ried C57BL/6 genomic DNA in the central region of the balancer interval (Fig 1A). To deter-
mine if recombinants 363 or 508 produced mutant embryos with the l11Jus27 phenotype,
timed matings were performed, and resulting embryos analysed at embryonic day (E) 10.5–
12.5. At these developmental stages, the l11Jus27 phenotype was apparent, with most mutant
embryos dying by E12.5 (Fig 1B). However, homozygous C57BL/6 embryos produced from
the cross of recombinant 363 to l11Jus27 heterozygotes did not display the l11Jus27 phenotype
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Fig 1. The l11Jus27 mouse line carries two embryonic lethal mutations, one of which is in Myh10. A: Two recombinant mice
show linkage of the phenotype (lethality) with distinct sub-regions of the mouse chromosome 11 balancer interval. The blue line
indicates the 129S5 non-mutagenised chromosome. The C57BL/6 region (red) in recombinant mouse 363 extends beyond the
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(Fig 1C). Instead, mutant embryos were viable past mid-gestation, and exhibited severe hydro-
cephalus in the mid-brain region from E11.5 (Fig 1C, arrows). We found that embryos gener-
ated from the cross of recombinant 508 did display the l11Jus27 phenotype (Fig 1B), indicating
that the l11Jus27 mutation is located in the region between the polymorphic markers D11MIT
322 and D11MIT35 on mouse chromosome 11.
Based on the new phenotype displayed in the offspring from recombinant mouse 363, we
concluded that two embryonic lethal mutations were present in the l11Jus27 mice, and that
mutant embryos carrying both mutations exhibited the more severe l11Jus27 phenotype. A
new line of mice displaying the hydrocephalus phenotype was generated from crossing recom-
binant 363 to balancer chromosome animals, so that the new mutation could be maintained in
trans to the balancer. This new mutant line was named EHC. Candidate gene analysis of the
C57BL/6 region inherited by EHC mice revealed Myh10 as a strong candidate gene. Myh10
encodes NMHC IIB, the heavy chain component of the NMIIB protein complex, and targeted
deletion of Myh10 results in late-gestation lethality with hydrocephalus and cardiac defects
[26, 33]. Therefore, due to similarities in phenotype, we sequenced Myh10 genomic DNA
from EHC mutant mice. We found a ‘G’ to ‘T’ transversion mutation in the splice donor site
following exon 18 (Fig 1D). This mutation causes exon 18 to be skipped from the Myh10 EHC
mutant transcript, producing a smaller product from an RT-PCR reaction performed with
primers in exons 17 and 19 (Fig 1E). An abnormal Myh10 transcript created from the fusion of
exon 17 and exon 19 was present in EHC mutant embryos (Fig 1F), while wild type embryos
contained a transcript with exons 17, 18, and 19 (Fig 1G).
EHC mutant embryos showed a reduction in full-length Myh10 transcript levels as analysed
by qPCR (Fig 2A) or RT-PCR amplifying the region from exons 17–19 (Fig 2B). The NMHC
IIB protein is a 230kDa molecule comprising 1976 amino acids [20, 21, 34]. The wild type
NMHC IIB protein sequence translated from exons 17 and 18 is shown in Fig 2C. The abnor-
mal fusion of exons 17 and 19 in the EHCMyh10 transcript causes a change in the reading
frame, resulting in a truncated protein (1–703 amino acids). Additionally, the final three
amino acids are divergent from the wild type sequence with a YEI to SEL change (Fig 2D,
boxed area). Using a C-terminal NMHC IIB antibody for western blotting, we confirmed that
full-length NMHC IIB protein is not detectable in EHC mutant embryos (Fig 2E). Modelling
the effect of the EHC mutation on the NMHC IIB protein demonstrated that the premature
stop-codon will cause truncation of the protein in the actin binding head domain, resulting in
the synthesis of NMHC IIB devoid of the coiled coil rod domain (Fig 2F). NMIIB is dependent
upon interactions between the heavy chain rod domains to associate into bipolar filaments in
order to exert its cellular function (Fig 2G) [20, 21]. We predict that if a truncated NMIIB pro-
tein was produced in EHC mutant embryos, this aberrant protein lacking the essential rod
domain would be unable to partake in molecular interactions and therefore be unable to exert
contractile force upon the actin cytoskeleton.
balancer chromosome endpoint at Trp53. B: l11Jus27 heterozygous and homozygous mutant embryos at E10.5, E11.5, and E12.5.
For this and all subsequent figures, images are representative findings from a minimum of n = 3 observations unless otherwise stated.
C: Dissections of embryos from crosses of l11Jus27 heterozygotes with recombinant 363 reveal that at E10.5 –E12.75 the l11Jus27
phenotype is not apparent in homozygous C57BL/6 embryos. At E11.5 and E12.75 embryos homozygous for C57BL/6 DNA have
prominent hydrocephalus (arrow), revealing a second embryonic lethal phenotype in the l11Jus27 line. D: Sequencing of the Myh10
gene reveals a ‘G’ to ‘T’ point mutation in the splice donor site of exon 18 (orange arrows). E: The Myh10 point mutation causes exon
18 to be skipped in the Myh10 mutant transcript. RT-PCR in three homozygous EHC mutant embryos (M) reveals a smaller transcript
than in one wild type (WT) embryo. The reduction in size of the PCR product is consistent with skipping exon 18. F: Sequencing
Myh10 transcript from mutant embryos confirms that exon 18 is missing, causing exons 17 and 19 to be joined. G: A wild type
transcript that contains exons 17, 18, and 19. The black and grey lines in (F) and (G) highlight the sequence from exon 17 and
sequence from exon 19 respectively shown in both the mutant and wild type. Scale bars: 1mm. Abbreviations: L27: l11Jus27; L:
molecular size ladder; Het: heterozygote; WT: wild type; M: mutant; neg: negative control.
https://doi.org/10.1371/journal.pgen.1007068.g001
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Fig 2. Predicted alterations to NMHC IIB protein in EHC mutants. A: Comparison of full-length Myh10
transcript levels in control (WT or het) and mutant embryos by qPCR. B: RT-PCR amplification products from
Myh10 is required for coronary vessel formation
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Confirmation of the EHC causative mutation by complementation test
To confirm that the EHC causative mutation had been correctly mapped to Myh10, and subse-
quently caused loss of NMHC IIB function, we performed a complementation assay with a
known Myh10 null allele, denoted as Myh10Δ. The Myh10Δ allele has a deletion of Myh10
exon 2 [33], and does not synthesise full-length NMHC IIB protein (S1A Fig). As with the
EHC mutants, homozygous Myh10Δ mutant embryos demonstrated late gestation embryonic
lethality and were not present at the expected Mendelian ratios at birth (S1B Fig, Chi squared
test p = 0.0035). Heterozygous EHC and Myh10Δ animals were intercrossed; the resultant
progeny were genotyped and analysed for embryonic lethality and developmental defects.
Analysis of Mendelian frequencies of EHC/Myh10Δ embryos at birth revealed a deviation
from expectations due to late gestation embryonic lethality (S1C Fig, Chi squared test,
p = 0.0278). These results indicated a failure of complementation between the two lines, and
provided strong support for the hypothesis that the Myh10 mutation causes the EHC pheno-
type by ablating NMHC IIB function.
EHC mutants display embryonic hydrocephalus and cardiac defects
We concluded that EHC mutant embryos were alive at E12.5 since a regular heartbeat was
observed at the time of dissection. We therefore examined the phenotype of EHC mutant embryos
at late gestation. At E13.5, there is still prominent hydrocephalus in the mesencephalic vesicle (Fig
3A and 3B). At E15.5, EHC mutant embryos often displayed oedema in the spinal cord region
(Fig 3C and 3D, arrowhead), whilst excess fluid within the mesencephalic vesicle persists (Fig 3C
and 3D, arrow). It was rare to recover EHC mutant embryos past E16.5, but the embryos that did
survive had abnormal dome-shaped heads, consistent with developmental hydrocephalus (Fig 3E
and 3F, arrow). Based on the reduced recovery of the EHC mutants from dissections after E16.5,
we conclude that the EHC phenotype causes late-gestation embryonic lethality, accompanied by
defects in cranial development due to severe hydrocephalus in the early embryo.
As cardiac defects have been previously described for a targeted deletion of NMHC IIB [23,
33, 35], we examined cardiac development in the EHC mutant mouse. We found several simi-
larities between the EHC cardiac phenotype and the defects described in the NMHC IIB knock
out. First, upon dissection at E11.5 we observed pericardial effusion and blood in the pericar-
dial sac of EHC mutant embryos (Fig 4B and 4D) and on the surface of the EHC mutant heart
(Fig 4D’), phenotypes consistent with cardiac developmental defects. Membranous ventricular
septal defects have been reported in NMHC IIB knock out animals [33, 35, 36]. However, we
found that the endocardial cushions are present and have fused in EHC mutant embryos at
E11.5 (Fig 4D, arrow), indicative of initial development of the septum. Later in gestation, EHC
mutants at E14.5 have a thin ventricular septum with tearing in the membranous region, sug-
gestive of a vulnerability to septal defects (Fig 4F, arrow). We also observed that EHC mutant
the region encompassing Myh10 exon 17–19 in wild type, het, and mutant samples. C: Myh10 wild type
transcript and protein sequence is shown for exons 17 and 18. The boxed area highlights the translation of
exon 18. Numbering refers to nucleotide positions of the Myh10 transcript, with the initiation codon ‘A’
considered base 1. D: Predicted protein sequence for the EHC mutant transcript. The boxed area highlights
the abnormal reading frame created by the fusion of exons 17 and 19, indicating that the mutant protein is
truncated. E: Western blot with a C-terminal NMHC IIB antibody reveals that EHC mutant embryos do not
produce full-length non-muscle myosin IIB. Actin is used as a loading control. F: Structural model of wild type
NMHC IIB protein displays the head domain (left). The region deleted in the EHC mutant is shown in blue. The
NMHC IIB protein predicted to be generated from the Myh10 mutant transcript in EHC mutants (right). G:
Schematic representation of wild type NMHC IIB dimers in complex with the essential light chains (ELC) and
regulatory light chains (RLC) to form mature non-muscle myosin IIB. The location of the EHC mutation in the
globular head domain of NMHC IIB is illustrated.
https://doi.org/10.1371/journal.pgen.1007068.g002
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Fig 3. EHC mutant embryo morphology. A: Heterozygous littermate at E13.5. B: EHC mutant displays
hydrocephalus in the mesencephalic vesicle (white arrow). C: Heterozygous littermate at E15.5. D: EHC
mutant at E15.5 displays reduced hydrocephalus (arrow), although oedema in the spinal cord region is
apparent (arrowhead). E: Heterozygous littermate at E17.5. F: EHC mutant has dome-shaped head (arrow),
Myh10 is required for coronary vessel formation
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ventricles display reduced trabeculation, a thinner compact myocardium, and disorganisation
of cells in the ventricular myocardium (Fig 4D and 4F, asterisk). In addition, we detected
defects in myocardial cytokinesis (S2A–S2D Fig), comparable to previously reported data
from NMHC IIB knock out mice [23, 33, 37]. We observed double-outlet right ventricle
(DORV), where the aorta erroneously stems from the right ventricle, in mutant embryos at
E16.5 (Fig 4H asterisk), similar to findings from NMHC IIB knock out mice [33, 36]. Interest-
ingly, DORV was not detected when NMHC IIB was specifically deleted in cardiomyocytes
consistent with developmental defects arising from embryonic hydrocephalus. Scale bars: 1 mm.
Abbreviations: MV: mesencephalic vesicle.
https://doi.org/10.1371/journal.pgen.1007068.g003
Fig 4. EHC mutants display defects in cardiac development. A: Heterozygous littermate control at E11.5
showing developing heart in pericardial sac. B: EHC mutant has pericardial effusion and blood visible in
pericardial sac (arrow). C: Transverse section of control littermate at E11.5. The boxed region indicates the
segment shown in panel C’. C’: Note the absence of blood cells on the cardiac surface and in the pericardial
space. D: Transverse section of EHC mutant at E11.5 showing enlarged atria. The boxed region indicates the
segment shown in panel D’. D’: Blood cells are present on the surface of the EHC heart (black arrow) and in
the pericardial space (orange arrow). E: In heterozygous littermates at E14.5 the ventricular chamber is
surrounded by a thick compact myocardium, which is highly organised. F: At E14.5, EHC mutants show a
reduced compact ventricular myocardium (indicated by asterisk), accompanied by a thinning of the ventricular
septal tissue (arrow). Note the abnormal atrial morphology and different localisation of the atria with respect to
the ventricle compared to control (E). G: Heterozygous heart at E16.5 shows expected ventricular vascular
connections and also coronary vessels on the cardiac surface (arrow). H: EHC mutant heart shows double-
outlet right ventricle (DORV) (asterisk) as well as an absence of surface coronary vessels (arrow). Note the
vesicle-like structures present on the ventricular surface. I: EHC/Myh10Δ and J: Myh10Δ/Myh10Δ hearts at
E16.5 similarly show DORV (asterisks) and ventricular vesicles (arrows). Scale bar = 200 μm (E, F), 1mm
(A-D, G-J). Abbreviations: Het: heterozygote; lb: limb bud; LA: left atria, LV: left ventricle, RA: right atria, RV:
right ventricle, VS: ventricular septum, Δ: Myh10Δ.
https://doi.org/10.1371/journal.pgen.1007068.g004
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[35]. However, the DORV phenotype was completely penetrant in EHC hearts at E16.5. Dur-
ing our morphological inspection of E16.5 hearts, we also observed that mutant hearts dis-
played an abnormally rounded ventricular morphology, which lacked a prominent ventricular
apex (Fig 4H–4J). In addition, EHC mutants displayed distended atria, abnormally positioned
in relation to the ventricles (Fig 4F and 4H), and the ventricular surface was decorated with
multiple blood filled vesicle-like structures (Fig 4D’ and 4H, arrows). These vesicles can be
observed as early as E11.5 and persist until embryonic lethality. Again, these malformations
were fully penetrant in mutant embryos by visual inspection at E16.5.
Additionally, the morphology of EHC/Myh10Δ and Myh10Δ/Myh10Δ embryonic hearts
closely resembles that of the EHC mutants (Fig 4I and 4J). Together, the phenotypic similarity
of EHC and Myh10Δ homozygous mutants, combined with the failure of the Myh10Δ allele to
complement the EHC allele, confirms that the EHC mutation causes complete loss of Myh10
function, resulting in the observed EHC cardiac abnormalities.
Mutant hearts lack coronary vasculature
It became strikingly apparent during our dissection observations that the EHC mutants lacked
blood-filled coronary vessels on their ventricular surface, in contrast to heterozygous EHC
control hearts (Fig 4G compared to 4H). The Myh10Δ homozygotes and EHC/Myh10Δ com-
pound heterozygote mutant embryos also displayed a lack of coronary vessels (Fig 4I and 4J).
To confirm that EHC and Myh10Δ mutant hearts lacked a mature coronary network, we per-
formed immunohistochemical analysis for markers of cellular components of the coronary
architecture, namely vascular endothelial cells (PECAM-1/CD31), and vascular smooth muscle
cells (SM22α). Heterozygous littermates at E16.5 displayed clear PECAM-1 immunoreactivity,
highlighting mature coronary vasculature in which vascular endothelial cells are organised into
a large and extensively branched vascular network (Fig 5A and 5B arrows). In contrast, EHC
mutants at E16.5 displayed only PECAM-1 immunoreactive surface cell clusters (Fig 5C and 5D
arrows). A similar staining profile was observed in EHC/Myh10Δ and Myh10Δ/Myh10Δ mutant
hearts (S3 Fig). To further examine the extent of coronary defects, we evaluated the localisation
of vascular endothelial and smooth muscle cells (vSMCs) at E14.5. In heterozygous Myh10Δ
controls, we observed intense PECAM-1 staining around the lumen of developing vessel struc-
tures, illustrating the presence of endothelial cells around the coronary vessels during matura-
tion (Fig 5E and 5F arrow). However, Myh10Δ homozygous mutant hearts displayed PECAM-1
staining surrounding clusters of blood cells on the cardiac surface (Fig 5G and 5H arrow), con-
sistent with results from whole mount PECAM-1 staining of EHC, EHC/Myh10Δ compound
heterozygotes and Myh10Δ homozygous mutant hearts (S3 Fig). Coronary endothelial cells are
present in a capillary network on the surface of EHC mutant hearts, but lack organisation into
larger vessels (S5J–S5K Fig). Smooth muscle cells were present in the heart of heterozygous con-
trol embryos (Fig 5I–5K), including surrounding coronary vessels (Fig 5J arrowheads). In the
interventricular septum region, SM22α distribution in Myh10Δ homozygous mutant hearts (Fig
5L) was similar to that of control hearts (Fig 5I). In the compact myocardium, Myh10Δ homozy-
gous mutants did not display organised clusters of smooth muscle cells or vascular structures
(Fig 5M and 5N). Together, these experiments demonstrate that EHC and Myh10Δ homozygous
mutant hearts display similar defects in coronary vessel formation.
NMHC IIB is not required in cardiomyocytes for coronary vessel
development
Prior research has demonstrated that mice with a cardiomyocyte-specific deletion of Myh10 are
viable [35], suggesting that coronary vessel development must not be severely compromised
Myh10 is required for coronary vessel formation
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Fig 5. EHC mutants lack mature coronary vessels. PECAM-1 immunohistochemistry reveals prominent coronary vessels (arrows) on the ventral (A)
and dorsal (B) surface of EHC heterozygous hearts. Only clusters of PECAM-1 expressing cells (arrows) are apparent on EHC homozygous mutant
ventral (C) and dorsal (D) heart surface, with no clear evidence of coronary vessels. E-F: Section immunofluorescence for PECAM-1 (green) on Myh10Δ
heterozygote at E14.5, demonstrating cells in myocardial region surrounding a developing vessel (arrow). G-H: Section immunofluorescence for
PECAM-1 on Myh10Δ homozygous mutant at E14.5, demonstrating staining of clusters of cells on cardiac surface (arrow), consistent with whole mount
staining in panels C-D. Staining for the smooth muscle cell marker SM22α reveals few smooth muscle cells within the interventricular septum region of
the heterozygote (I) and Myh10Δ homozygous mutant (L). SM22α expressing cells are localised around a developing coronary vessel (white dashed
circle) in heterozygous control hearts (J-K, arrowheads), and nucleated blood cells within the vessel can be visualised with DAPI (yellow arrow). No such
structures are present in Myh10Δ homozygous mutant hearts, and smooth muscle cells expressing SM22α are less clustered in mutant hearts (M-N,
arrowheads). Cell nuclei were labelled with DAPI (blue). Scale bars: A-D = 1 mm, E-H = 100 μm, I and L = 50 μm, J-K and M-N = 25 μm. Abbreviations:
CV: coronary vessel, epi: epicardium, IVS: interventricular septum, myo: myocardium, PECAM: platelet endothelial cell adhesion molecule-1, Δ:
Myh10Δ.
https://doi.org/10.1371/journal.pgen.1007068.g005
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when NMHC IIB function has been lost from cardiomyocytes. To investigate the dependence
of coronary vessel development on cardiomyocytes NMHC IIB activity, we implemented the
previously described strategy [35] to delete Myh10 exon 2 in cells expressing the cardiomyo-
cyte-specific α-Myosin Heavy Chain-Cre (αMHC-Cre) transgene. Confirmation of the genomic
deletion of Myh10 exon 2 in cardiac cells, but not tail, brain, or liver cells was demonstrated by
genomic PCR for primers surrounding Myh10 exon 2 (Fig 6A). These primers generate a 1 Kb
product when exon 2 is present in the genome, and a 600bp product after deletion of Myh10
exon 2. The 600bp deletion product is visible only in heart tissue (Fig 6A, arrow). We further
demonstrated the cardiomyocyte specificity of the deletion of Myh10 by isolating cardiac cells,
dissociating them in culture, and subjecting the cells to fibroblast or cardiomyocyte culture pro-
tocols [38, 39]. NMHC IIB protein persists in fibroblast cells, which show characteristic mor-
phology (Fig 6B–6D), but not in cardiomyocytes (Fig 6E–6G), which also have distinctive
morphology in culture. Histological sections of hearts at E18.5 from control and Myh10 cardio-
myocyte-specific knock out embryos were examined by immunofluorescence for NMHC IIB
and cardiac troponin T expression (Fig 6H–6K). Embryos inheriting the αMHC-Cre transgene
and homozygous Myh10 floxed alleles had reduced NMHC IIB expression within the myocar-
dium, although expression of NMHC IIB can be seen in non-cardiomyocyte cell populations
such as the endocardial cells present in the valve leaflets (Fig 6J, white arrow). Analysis of vessel
development in control embryos and cardiomyocyte knockouts reveals the presence of blood
cells in organised vessels on the cardiac surface, visible directly in dissections at E18.5 (S4A–
S4D Fig), with PECAM-1 staining at E16.5 (S4E and S4F Fig), and following DAB staining of
blood cells within heart tissue at E15.5 (Fig 6L–6O). These results confirm that cardiomyocyte
expression of NMHC IIB is not required for the development of coronary vessels.
EHC mutants display abnormal epicardial cell morphology
Due to the evidence that cardiomyocyte NMHC IIB is not required for coronary vessel devel-
opment, we sought to determine if defects in epicardial cell function may therefore underpin
the EHC mutant phenotype. A number of seminal studies have demonstrated that the epicar-
dium plays a crucial role in the formation of the coronary vessels during mammalian develop-
ment [15, 40–45]. As the coronary vessels incorporate cells and signals from the epicardium
and sinus venosus during their development [13, 15], we investigated if the specification of the
epicardial precursor, the proepicardial organ, and the sinus venosus occurred correctly in EHC
mutant embryos. In situ hybridisation for Tbx18, a proepicardial marker [46], and Shox2,
which is expressed in the sinus venosus [47, 48], showed that these molecular markers are
expressed in a similar pattern in heterozygous and EHC mutant developing embryos (Fig 7A–
7D, arrows), suggesting that these coronary vessel precursor tissues were present during early
development in mutant embryos.
Histology and transmission electron microscopy revealed that at E14.5, heterozygous hearts
showed the formation of a characteristic epithelial layer on the surface of the myocardium (Fig
7E–7G) with flattened epicardial cells (Fig 7F, arrow). Although epicardial cells were clearly
evident on the surface of the EHC mutant heart (Fig 7H, arrow), these cells had an unusual
morphology compared to controls (Fig 7I, arrows). In addition, the EHC epicardium did not
form a contiguous epithelial layer, and individual epicardial cells did not appear to form
appropriate contacts with adjacent cells (Fig 7I, asterisk). The formation and maintenance of
epicardial cell-cell gap junctions has previously been shown to be essential for correct epicar-
dial cell function [49]. Interestingly, the ultrastructure of the subepicardial cell nucleus dis-
played an abnormal, multi-folded morphology, indicating defects in the maintenance of
correct cellular architecture (Fig 7I, arrowhead). We calculated the percentage of epicardial
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Fig 6. NMHC IIB is not required in cardiomyocytes for coronary vessel formation. A: Genomic PCR on tissues isolated from
mice carrying the αMHC-Cre transgene and Myh10 flox/+ alleles shows a PCR product of 600 bp in cardiac tissue, consistent with
deletion of Myh10 exon 2 from the genome (arrow). This product is not seen in tail, brain, or liver tissue. PCR results from a
Myh10Δ/+ heterozygous animal are shown for the corresponding tissues, with the 600 bp product present in all tissues. The 1 Kb
product represents the Myh10 allele lacking exon 2 deletion. Products were sequenced to confirm specificity of PCR reactions. B:
NMHC IIB protein (green) and C: actin (red; phalloidin stain) localisation in fibroblasts cultured from αMHC-Cre; flox/flox hearts. D:
Merged image shows DAPI labeling of nuclei (blue). E: NMHC IIB protein (green) and F: actin (red; phalloidin stain) localisation in
cardiomyocytes cultured from αMHC-Cre; flox/flox hearts. G: Merged image shows DAPI labelling of nuclei (blue). H: Expression
patterns of NMHC IIB (white) and cardiac Troponin T (red), and nuclei stained with DAPI (blue) in αMHC-Cre; Myh10+/+ control
embryo with presence of coronary vessel (orange arrow). NMHC IIB expression is seen throughout heart including valve tissue
(white arrow). Co-expression of NMHC IIB and cTnT appears pink. I: Higher magnification image of cardiac tissue from
αMHC-Cre; Myh10+/+ control embryo. J: Expression patterns of NMHC IIB (white) and cardiac Troponin T (red), and nuclei
stained with DAPI (blue) in αMHC-Cre; Myh10 flox/flox control embryo with presence of coronary vessel (orange arrow). NMIIB
expression is seen in valve tissue (white arrow) but reduced in myocardial region of heart, and is absent from cTnT positive cells,
so that the pink staining indicating NMHC IIB and cTnT co-expression is reduced in the myocardium. K: Higher magnification
image of cardiac tissue from αMHC-Cre; Myh10 flox/flox control embryo. Epicardial expression of NMHC IIB persists (white
arrows). L: Ventral view of cardiac surface stained with DAB to identify blood cells in αMHC-Cre; Myh10+/+ heart (arrow). M:
Dorsal view of cardiac surface stained with DAB to identify blood cells in αMHC-Cre; Myh10+/+ heart (arrows). N: Ventral view of
cardiac surface stained with DAB to identify blood cells in αMHC-Cre; Myh10 flox/Δ heart (arrows). O: Dorsal view of cardiac
surface stained with DAB to detect endogenous peroxidase activity from blood cells in αMHC-Cre; Myh10+ flox/Δ heart (arrows).
Blood cells within vessels are present on the cardiac surface of cardiomyocyte-specific Myh10 mutant hearts. Similar results were
seen for αMHC-Cre; Myh10 flox/flox hearts. Scale bars: B-G = 50 μm, H and J = 100 μm, I and K = 15 μm, L-O = 400 μm.
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cells with visually abnormal morphology in control and EHC mutant EM images, finding a sta-
tistically significant increase in the percentage of abnormal cells in EHC mutants (S2E–S2G
Fig; Fisher’s exact test p<0.001).
The epicardium deposits extracellular matrix into the subepicardial space, which separates
it from the underlying myocardium and is thought to play a critical role in the molecular com-
munication between these tissues during embryonic development, homeostasis, and response
to injury [13, 50, 51]. To evaluate possible defects in epicardial ECM deposition in the EHC
mutants, we next analysed the subepicardial ECM by staining E11.5 cardiac sections with
Alcian blue, a marker of glycosaminoglycans (GAGs) (Fig 7G and 7J). Prominent Alcian blue
staining clearly delineated the subepicardial ECM in control hearts (Fig 7G, arrow). In con-
trast, EHC mutants lacked Alcian blue staining at the boundary between the epicardium and
myocardium (Fig 7J, arrow), suggestive of abnormalities in the subepicardial ECM. Both
mutant and control embryos display similar Alcian blue staining in the endocardial cushion
mesenchyme (S2H–S2K Fig), illustrating that the localisation profile of GAGs within the heart
is not universally disrupted in EHC mutants.
To evaluate potential requirements for NMHC IIB in other cardiac cell types with a role in
coronary vessel development, we investigated whether or not NMIIB ablation disrupted the
development of the endocardium by analysing the localisation of the endocardial marker
endomucin, in both heterozygous control and Myh10Δ homozygous mutants E11.5 hearts (Fig
7K–7P). Myh10Δ homozygous mutants were utilised in these experiments to facilitate geno-
typing, as the loss of Myh10 exon 2 can be determined from a single PCR rather than requiring
genomic sequencing as needed to detect the EHC point mutation. No aberrations in endomu-
cin staining were detected in Myh10Δ homozygous mutant embryos (Fig 7N–7P), suggesting
that the formation of the endocardium is not dependent upon NMIIB function. Moreover, the
developing atrioventricular valves, derived from endocardial tissue, are present in heterozy-
gous control and EHC mutant embryos at E14.5 and E16.5 (S5A–S5D Fig). As the formation
of cardiac valve structures is highly dependent upon a functional endocardium [13, 52], the
presence of these structures in EHC mutants supports the hypothesis that endocardial function
is not significantly impaired following loss of NMHC IIB. A recently published complemen-
tary study has demonstrated that coronary vessel development is impaired when NMHC IIB is
deleted specifically within the epicardium [53], supporting our findings that epicardial abnor-
malities in EHC mutant mice contribute to defective coronary vessel development.
NMHC IIB is the predominant form of NMII in the embryonic heart and
epicardium
We sought to establish why the epicardium in particular demonstrates abnormalities following
NMHC IIB ablation that are not exhibited in other tissue types. There are three NMHC II iso-
forms, IIA, IIB, and IIC, encoded by Myh9, Myh10 and Myh14 respectively in the mouse [20,
21]. The NMHC IIB null mouse displays developmental defects primarily in the brain and
heart, which the authors attribute to an enrichment of NMHC IIB in these tissues [33, 37, 54].
However, the relative expression levels of individual NMHC II isoforms have not been
explored specifically within the embryonic epicardium. We analysed NMHC II protein levels
in control embryonic hearts using immunofluorescent microscopy. This analysis revealed that
NMHC IIB is the predominant NMHC II isoform found in the E14.5 heart, and moreover,
Abbreviations: αMHC-Cre: Tg(Myh6-cre)2182Mds/J, CM: cardiomyocyte, cTnT: cardiac troponin T, Fibro: fibroblast, NMIIB: NMHC
IIB, Δ: Myh10Δ.
https://doi.org/10.1371/journal.pgen.1007068.g006
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Fig 7. EHC mutants display epicardial defects. A: In situ hybridisation demonstrating Tbx18 expression in the
proepicardial organ of heterozygous and B: EHC homozygous mutant E9.5 embryos (arrows). C: Shox2 expression is
detected in the sinus venosus of heterozygous and D: EHC homozygous mutant E9.5 embryos (arrows). The
expression patterns of Tbx18 and Shox2 are indistinguishable between controls and EHC mutants. E: Heterozygous
embryos have an epithelial layer comprised of epicardial cells coating the developing ventricle at E14.5. F: Electron
microscopy showing E16.5 epicardial cells from heterozygous mice having a flattened morphology (arrow) and forming a
contiguous layer with adjacent cells. G: Alcian blue staining reveals a layer of glycosaminoglycans in the extracellular
matrix between the epicardium and myocardium in heterozygotes at E11.5 (arrow). H: Epicardial cells are present on the
surface of the EHC homozygous mutant myocardium (arrow) at E14.5. I: Mutant epicardial cells are irregular in shape
and exhibit a rounded morphology (arrows), which generates gaps between neighbouring cells (asterisk). Subepicardial
cells display evidence of disrupted cellular architecture maintenance (arrowhead). J: EHC mutants lack Alcian blue
staining in the subepicardial tissue domain (arrow). K-M: Endomucin immunofluorescence staining (red) of control E11.5
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within the epicardium (Fig 8A–8C, arrows). All NMHC II isoforms were detectable in the
developing lung (Fig 8D–8F, arrows), as previously described [37]. In addition, at E11.5 we
found NMHC IIB together with IIA, were abundant in whole heart protein extracts probed by
western blotting (Fig 8G and 8H). Somewhat surprisingly, we found that levels of NMHC IIA
appeared to be diminished in NMHC IIB ablated samples (Fig 8G), whilst NMHC IIC was not
detectable in either control or mutant preparations (Fig 8I). In light of this, we sought to deter-
mine the relative abundance and subcellular localisation of NMHC IIA and IIB in enriched
epicardial cell cultures derived from E11.5 heart explants by immunocytochemistry. In both
control and mutant cultures, NMHC IIA appeared to be primarily localised to the cell periph-
ery in cells at both the leading edge and within the culture monolayer (Fig 8J–8L, arrows). In
comparison, not only was fluorescent signal notably increased for NMHC IIB (Fig 8M and
8N), its subcellular localisation appeared to be more diffuse throughout the cell body (Fig 8N,
asterisks), and frequently associated with cytoskeletal stress fibres (Fig 8N, arrows). As
expected, NMHC IIB was not detectable in NMIIB ablated cultures (Fig 8O). Interestingly,
mutant epicardial cells did not display either an increase in NMHC IIA signal intensity, or
altered NMHC IIA subcellular distribution when compared to controls (Fig 8L compared to
8J). Higher magnification images of control hearts at E11.5 and E14.5 demonstrate NMHC IIB
protein localisation to the epicardium (Fig 8P and 8R), with higher levels of epicardial expres-
sion found at E14.5 (Fig 8R) as compared to E11.5 (Fig 8P). We did not detect any immunoflu-
orescent signal in Myh10Δ homozygous mutant hearts at either E11.5 or E14.5 using the
NMHC IIB C-terminal antibody (Fig 8Q and 8S). Together, these data suggest that NMHC IIB
is expressed at both a higher abundance in the epicardium, and in distinct subcellular regions
to other NMHC II isoforms. Consequently, NMIIB may be serving a specialised function in
the epicardial cells that cannot be compensated by other NMII isoforms when NMIIB is lost,
thus exposing epicardial dysfunction.
EHC epicardial cells do not exhibit migration defects in vitro
The formation of the epicardium is wholly reliant upon the migration of cells from the PEO to
the surface of the developing myocardium [8]. NMHC IIB has been shown to play an impor-
tant role in cell migration, through the generation of traction forces, and guidance of direc-
tional persistence [20, 21, 28, 36]. In light of this, we sought to investigate whether NMHC IIB
null epicardial cells demonstrated motility defects in vitro by performing a scratch wound
assay on epicardial cells cultured from embryonic heart explants as previously described [55].
Epicardial cells from control (+/+ or Myh10Δ/+) and NMHC IIB null (Myh10Δ/Myh10Δ)
E11.5 hearts were enriched and cultured for 48 hours to confluence on gelatin-coated 24-well
plates. The Myh10Δ line was used for these experiments to expedite genotyping. The epicardial
nature of the resultant cell populations was confirmed by immunostaining for the epithelial
marker, ZO1, epicardial marker, Wt1 (Wilms Tumour 1), and the epithelial ‘cobble-stone’
morphology of filamentous actin staining with rhodamine phalloidin (Fig 9A and 9B). These
epicardial monolayers were scratched with a P10 pipette tip and wound closure was imaged
over a 20-hour period (S1 and S2 Movies). For each image series, we identified 10 cells at the
leading edge of the wound at T0, and manually tracked their migration (Fig 9C and 9D). Cell
coronal cardiac sections delineates the ventricular endocardium. N-P: Endomucin distribution in Myh10Δ homozygous
mutants is indistinguishable from controls. Areas shown at higher magnification in panels L-M and O-P are indicated with
boxes on images K and N. Nucleated erythrocytes in panels M and P are indicated by asterisks. Scale bars:
A-D = 250 μm, E and H = 60 μm, F and I = 5 μm, G and J = 125 μm, K and N = 200 μm, L and O = 100 μm, M and
P = 50 μm. Abbreviations: H&E: haematoxylin and eosin, TEM: transmission electron micrograph Tr: trabeculae, Δ:
Myh10Δ.
https://doi.org/10.1371/journal.pgen.1007068.g007
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migration speed and directional persistence were subsequently analysed using ImageJ. Some-
what surprisingly, we found that NMHC IIB null epicardial cells exhibited normal migratory
behaviour when compared to controls, with no significant difference in either the average
migration speed (Fig 9E, Mann-Whitney, p = 0.6717), or directional persistence (Fig 9F,
Mann-Whitney, p = 0.2494). This finding suggests that epicardial cells do not require NMHC
IIB to exhibit normal migratory behaviour in vitro.
EHC epicardial-derived cells demonstrate disrupted functionality in vivo
It is well documented that during development, a sub-population of epicardial cells undergo
EMT and give rise to epicardial-derived cells that have acquired the ability to invade the under-
lying myocardium, where they differentiate into multiple cell lineages, including interstitial
and perivascular fibroblasts and vascular smooth muscle cells [15, 45]. In addition to this cellu-
lar contribution, it is suspected that EPDCs regulate myocardial development through expres-
sion of paracrine signalling molecules [56–60]. It is clear that the correct execution of
epicardial EMT is essential for both coronary and myocardial development. Since we did not
detect epicardial motility defects in vitro, we examined epicardial cell migration into the
underlying cardiac tissues in vivo by evaluating the localisation of cells expressing the epicar-
dial marker Wt1 in EHC mutant and control embryos (Fig 10A–10G). Measurements of the
distance between Wt1 positive cells in the ventricular myocardium of E14.5 hearts (Fig 10C
and 10D, yellow crosshairs) and the cardiac surface indicated that EHC EPDCs had not pene-
trated as deeply into the myocardium as EPDCs in control hearts (Fig 10H, Mann Whitney,
p<0.0001). Consequently, the majority of EHC EPDCs resided in a tightly restricted region of
the subepicardial space (Fig 10F and 10I) or specifically around the blood-filled ventricular
vesicles apparent in mutant hearts (Fig 10G). To confirm that the cells we detected at the car-
diac surface were epicardial cells, we used the marker Raldh2. We found that Raldh2 express-
ing cells are located at the cardiac surface at E11.5 and E14.5 in both heterozygous control and
Myh10Δ homozygous mutants (Fig 10K–10P). Quantification of the number of Raldh2 posi-
tive cells per length of epicardium reveals a significant increase in epicardial cell number in
Myh10Δ homozygous mutants at both E11.5 and E14.5 when compared to control littermates
(Fig 10J). We also evaluated vimentin expression at the cardiac surface in EHC mutant
Fig 8. NMHC IIB is the predominant form of NMII in the embryonic heart and epicardium. A-C:
Immunohistochemical comparison of the three different NMHC II isoforms (green) in the Myh10Δ/+ E14.5
heart. NMHC IIB is the predominant isoform, and shows intense staining in the epicardium (B, arrows). D-F:
E14.5 embryonic lung tissue was used as a control for the NMII isoform immunohistochemical analysis
(arrows). Cell nuclei are stained with DAPI (blue). G-I: Western blot analysis of NMII isoforms in E11.5 Myh10Δ
heterozygous control and homozygous mutant whole heart protein extracts. Protein extract from adult mouse
lung was run as a positive (+ve) control. NMIIA and IIB are found in relative abundance at this developmental
stage in heterozygous hearts (G and H). As expected, NMIIB is absent from mutant samples (H, lane 3), which
also show a reduction in NMIIA (G, lane 3). NMIIC is not detectable in either control or mutant samples (I).
Protein extracts pooled from at least n = 3 hearts for each genotype. J-O: Immunocytochemistry for the
predominant IIA and IIB isoforms in Myh10Δ heterozygote (J, K, M and N) and mutant (L, O) epicardial cell
cultures from E11.5 heart explants. Note localisation of NMIIA to the periphery of epicardial cells (J, K, arrows),
whilst NMIIB is localised throughout the whole cell body (M, N, asterisks), and is frequently associated with
actin stress fibres (M, N, arrow). Consistent with western blot analysis (H), NMHC IIB is not detectable in
mutant samples (O). Images representative of cell cultures obtained from four hearts per genotype. P: NMIIB
immunofluorescence (green) in E11.5 control sample. NMIIB is expressed in the epicardium (arrow). Nuclei are
labeled with DAPI (blue). Q: NMIIB expression in Myh10Δ homozygous mutant heart at E11.5. R: NMIIB
immunofluorescence (green) at E14.5 in control sample. NMIIB is highly expressed in the epicardium (arrow).
Nuclei are labeled with DAPI (blue). S: NMIIB expression in Myh10Δ homozygous mutant heart at E14.5.
NMIIB is not detectable in Myh10Δ homozygous mutant samples, consistent with western blot (H) and cell
culture results (O). Scale bars: A-F, J, L, M and O = 100 μm, K, N, P-S = 50 μm. Images in A-C and D-F
obtained at same magnification. Abbreviations: Δ: Myh10Δ.
https://doi.org/10.1371/journal.pgen.1007068.g008
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Fig 9. NMHC IIB ablated epicardial cells do not show migration defects in vitro. A: Cells cultured from E11.5
Myh10Δ/+ heterozygote and B: Myh10Δ homozygous mutant heart explants form an epicardial monolayer. Epicardial
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embryos and heterozygote controls (Fig 10Q–10T). We did not detect increased vimentin
staining in EHC mutant embryos, indicating that there is not an increase in mesenchymal cell
populations at the surface of the EHC heart. These in vivo results mirror the defects exhibited
in other mouse models with compromised epicardial cell function [32, 61–63]. In addition, an
in vivo cell migration defect may well be predicted from previous studies in which NMHC IIB
is ablated, or its activation inhibited [28, 32]. Together, these data provide a strong evidence
base to support our hypothesis that epicardial cell abnormalities contribute to the coronary
vessel defects displayed by EHC mutant mice.
The ECM environment is altered in NMHC IIB mutant hearts
Following the observation that Myh10Δ homozygous mutant epicardial cells display altered
migration in vivo, but not in scratch wound assays in vitro, we hypothesised that the coronary
vessel development defects in the EHC and Myh10Δ mutant embryos might be due to an
altered in vivo environment affecting epicardial derived cell migration. We have shown that
Alcian blue staining for GAGs was reduced in the EHC subepicardial ECM (Fig 7G and 7J).
Since GAGs constitute a major molecular component of the extracellular matrix, we hypothe-
sised that the loss of NMIIB disrupts ECM protein distribution in the developing heart, thus
hindering epicardial cell motility or migration in vivo. We therefore evaluated the expression
of laminin and fibronectin, ECM components documented to be expressed in the human
embryonic heart [64]. Fibronectin is of interest particularly in the developing epicardium,
since it has been shown to be required for directional persistence during epicardial cell migra-
tion [65]. In the mouse heart, fibronectin has been reported to localise to the epicardium from
E12.5 to E16.5, where it co-localises with collagen I [66]. To evaluate ECM distribution we per-
formed immunofluorescence for laminin, fibronectin, and collagen I in Myh10Δ/+ control
and Myh10Δ homozygous mutant hearts at E11.5 and E14.5. We found that laminin, fibronec-
tin and collagen I were abundantly present in the subepicardial ECM of control hearts, and
indeed, throughout the ventricular myocardium (Fig 11A–11C, arrows). The distribution of
these ECM components was altered in Myh10Δ homozygous mutant hearts, with little detect-
able staining in the epicardial layer and generally reduced levels throughout the heart (Fig
11A–11C, arrows). Quantification of the staining intensity in the epicardial region relative to
staining intensity in the myocardial region on the same tissue section was performed. All ECM
components analysed demonstrated a significantly reduced ratio of expression in Myh10Δ
homozygous mutants at E11.5 and E14.5 (Fig 11D), suggesting that the extracellular environ-
ment of the mutant heart has been altered. Furthermore, Myh10Δ homozygous mutant epicar-
dial explants cultured independently from myocardial cells display an altered pattern of
fibronectin distribution, with poor organisation and a reduced network of fibrils (S6 Fig), con-
firming that mutant epicardial cells have an impaired ability to produce fibronectin.
status was confirmed by positive staining for the epithelial marker ZO-1 (left panels), and the epicardial marker, Wt1
(centre panels). Rhodamine-phalloidin staining of the actin cytoskeleton also revealed characteristic ‘cobblestone’
morphology, indicative of an epithelial cell population (right panels). C: Control and D: mutant epicardial monolayers were
scratched at T0 (left panels) and imaged at 10-minute intervals for 20 hours. The migration of ten cells per field of view was
tracked using ImageJ (right panels, coloured lines). E: Graph showing the subsequent comparison of mean cell migration
speed (control = 0.3099μm/min, mutant = 0.3098μm/min, Mann-Whitney U-test p = 0.6717). F: Graph showing the
comparison of cell migration directional persistence (control = 0.7342, mutant = 0.7411, Mann-Whitney U-test p = 0.2494).
Total tracked cells = 240 control and 270 mutant. Cultures were generated from at least four hearts for each genotype.
Control refers to data compiled from both wild type and Δ/+ genotypes. Scale bars: 250 μm. Abbreviations: Δ: Myh10Δ.
https://doi.org/10.1371/journal.pgen.1007068.g009
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Fig 10. EHC epicardial-derived cells show defective migration in vivo. A: Representative images of Wt1 immuno-stained coronal
cryo-sections of EHC heterozygous and B: homozygous mutant E14.5 hearts. The dashed box indicates the area of ventricular wall
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Analysis of epicardial cell apoptosis, proliferation, and signaling in
NMHC IIB mutants
Correct deposition of the cardiac ECM is necessary for appropriate cardiac development [67].
In the adult heart, alterations in ECM composition are associated with apoptosis [68]. After
detecting ECM defects in NMHC IIB ablated mutants, we therefore assessed apoptosis in the
Myh10Δ homozygous mutant heart at E14.5 using a TUNEL assay, and compared our findings
to control samples (Fig 12A–12G). At this developmental stage, control hearts displayed low
levels of apoptosis in both the epicardium and underlying myocardium (Fig 12A and 12B). We
found a small but statistically significant increase in the average number of apoptotic cells
within the mutant myocardium, compared to control littermates (Fig 12G; Mann Whitney U
test, p<0.006). In contrast, whilst the mutant epicardium also displayed elevated apoptosis
rates when compared to controls, this finding was not statistically significant (Fig 12G; Mann
Whitney U test p = 0.07). Similarly, no statistically significant difference was observed between
the number of apoptotic cells in activated caspase-3 stained control (Fig 12H) and mutant (Fig
12I) hearts during early development at E9.5 (Fig 12J; unpaired 2-tailed Mann-Whitney U-
test, p = 0.9292). These data suggest that loss of NMHC IIB does not cause significant epicar-
dial apoptosis.
We next sought to establish whether the function of EHC epicardial cells was compromised
prior to EPDC migration, specifically focusing on the process of epicardial EMT. Analysis of
the proliferation marker phosphohistone H3 (PHH3) revealed a distinct increase in prolifera-
tion within the epicardium of EHC mutants at E14.5 as compared to controls (Fig 13A–13D,
arrows; Fig 13E, unpaired t-test, p<0.0001). We found no significant difference in cell prolifer-
ation in the underlying cardiac tissue between controls and EHC mutant hearts (Fig 13E,
unpaired t-test, p = 0.1684), nor in total cardiac tissue between control and Myh10Δ homozy-
gous mutant hearts at E9.5 (S6C Fig, unpaired t-test, p = 0.57). This finding is consistent with
a reduced incidence of EMT induction, as cells undergoing EMT attenuate cell division in
favour of changes to cell morphology [69]. Correspondingly, we examined the localisation of
the EMT marker, Snail, within the epicardium at E14.5. Similarly, we found that the EHC
mutants demonstrated a reduction in the number of Snail positive epicardial cells (Fig 13F–
13I, arrowheads). Recently it has been reported that NF-κB signaling is required downstream
used for measurement analysis in (C) and (D). C: Wt1 positive epicardial-derived cells were marked with yellow crosshairs in
heterozygous and D: mutant hearts. The distance between these cells and the cardiac surface (C-G: dashed line) was manually
measured using ImageJ. E: Wt1 positive cells (white) in the heterozygous heart can be seen at the cardiac surface (dashed line)
indicating localization in the epicardium, as well as in deeper cardiac tissue below the dashed line. F: EHC mutants have Wt1 positive
cells (white) primarily at the cardiac surface (dashed line), but these cells are organised into abnormal clusters (arrowheads), with few
cells at deeper positions in the underlying myocardium. G: Wt1 positive cells surround the ventricular surface blisters (arrows) present
in EHC mutant hearts. H: Graph comparing the mean migration distance of Wt1 positive cells: Het = 33.37 μm (+/-1.197 μm SEM,
n = 975), mutant = 20.14 μM (+/-0.8136 μm SEM, n = 1180), Mann-Whitney U-test p = <0.0001). I: Histogram showing the relative
frequency of Wt1 positive cells at increasing depths within the myocardial wall. A higher proportion of mutant Wt1 positive cells reside
in the subepicardial region (<50 μm from the apical epicardial boundary) compared to controls. J. Comparison of the mean number of
Raldh2 expressing cells found on the cardiac surface of hearts per unit of epicardial length for each genotype at E11.5 and E14.5.
Mean number of epicardial cells/100μm in E11.5 controls = 7.975 (+/- 0.4008, n = 4) and mutants = 11.93 (+/- 1.145, n = 7); Mean
number of epicardial cells/100μm in E14.5 controls = 7.3 (+/- 0.4243, n = 4) and mutants = 11.27 (+/- 0.9502, n = 10). A significant
difference is detected between genotypes at E11.5 (2-tailed unpaired t test, p = 0.0335) and E14.5 (2-tailed unpaired t test,
p = 0.0257). Error bars represent standard error of the mean. K: Raldh2 protein localisation (red) in Myh10Δ heterozygous control and
L-M: Myh10Δ homozygous mutant heart at E11.5. Sections from two different embryos are shown. N: Raldh2 protein localisation (red)
in Myh10Δ control and O-P: Myh10Δ homozygous mutant heart at E14.5. Sections from one embryo at different cardiac depths are
shown (O-P). Q: Vimentin immunofluorescence in E14.5 control heart. Spindle-shaped mesenchymal cells are present (arrow). R:
Merged image showing nuclei (blue). S: Vimentin immunofluorescence in E14.5 EHC mutant heart. Spindle-shaped mesenchymal
cells are present (arrow). T: Merged image showing nuclei (blue). The epicardial boundary with the myocardium is labeled with a
dashed line. Scale bars: A and B = 250 μm, C, D, Q-T = 100 μm, E-G = 50 μm, K and N = 25 μm. Abbreviations: epi: epicardium, myo:
myocardium.
https://doi.org/10.1371/journal.pgen.1007068.g010
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Fig 11. Examination of ECM composition in Myh10Δ control and mutant embryos. A: Laminin
immunofluorescence (green) is present at E11.5 and E14.5 in the Myh10Δ heterozygous ventricular
myocardium and is continuously distributed in the epicardium (arrow). Myh10Δ homozygous mutants show
reduced laminin immunoreactivity in the epicardium (arrow) at both E11.5 and E14.5. Nuclei are marked with
DAPI (blue). B: Fibronectin immunofluorescence (green) is present at E11.5 and E14.5 in the Myh10Δ
heterozygous ventricular myocardium and is continuously distributed in the epicardium (arrow). Myh10Δ
homozygous mutants appear to have reduced signal, especially in the epicardium (arrow) at E11.5 and E14.5.
Nuclei are marked with DAPI (blue). C: Collagen 1 immunofluorescence (green) is present at E11.5 and E14.5
in the Myh10Δ heterozygous ventricular myocardium and is continuously distributed throughout the
epicardium (arrow). Myh10Δ homozygous mutants have reduced collagen 1 signal in the epicardium (arrow)
at E11.5 and E14.5. Nuclei are marked with DAPI (blue). Genotypes and developmental stages are labeled on
the image. D: Quantification of the ratios of expression levels of epicardial immunofluorescence intensity to
myocardial immunofluorescence intensity for each protein. Three embryos of each genotype were analysed,
with measurements taken from five different areas of three different sections from each embryo. All markers
and time points showed a statistically significant reduction (*) in immunofluorescence intensity of the
epicardium relative to the myocardium in Myh10Δ homozygous mutants as compared to controls (two-tailed t-
test, p<0.05). Ratios of expression for each genotype were compared to each other for each marker and
developmental stage. Error bars represent standard deviation. Genotypes, markers and stages are labeled on
the graphs. Scale bars: 15 μm. Abbreviations: Lam: laminin, FN: fibronectin, Col1: Collagen I.
https://doi.org/10.1371/journal.pgen.1007068.g011
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Fig 12. Apoptosis in Myh10Δmutant hearts. A: TUNEL analysis (green) of Myh10Δ heterozygous heart at E14.5 shown with nuclei stained with DAPI
(blue). B: Single channel of TUNEL staining from (A). Apoptotic cells (arrowhead) are present along with autofluorescent erythrocytes (asterisk). C:
Autofluorescence of erythrocytes (red) from (A). D: TUNEL analysis (green) of Myh10Δ homozygous mutant heart at E14.5 shown with nuclei stained for
DAPI (blue). E: Single channel of TUNEL staining from (D). Apoptotic cells (arrowhead) are present along with clusters of erythrocytes (asterisks). F:
Autofluorescence of erythrocytes (red) from (D). G: Graph comparing mean number of TUNEL positive cells as a proportion of total cells in either the
epicardium, or myocardial wall. Mean percentage of apoptosis in control = 0.4484% (+/- 0.3082%), and mutant epicardium = 1.762% (+/- 0.662%) (unpaired
2-tailed Mann-Whitney U-test, p = 0.0744). Mean percentage of apoptosis in control = 0.4532% (+/- 0.204%), and mutant myocardial wall = 1.097% (+/-
0.2132%) (unpaired 2-tailed Mann-Whitney U-test, p = 0.0053). Three hearts per genotype and six non-consecutive sections per heart were analysed. H:
Sagittal section of control and I: Myh10Δ homozygous mutant hearts at E9.5 showing immunofluorescence for activated Caspase-3 (turquoise, arrows), with
nuclei visualised with DAPI (blue). J: Graph comparing mean number of activated caspase-3 positive cells as a percentage of total cells in cardiac sections of
control and mutant E9.5 hearts. Mean percentage of apoptosis in control = 0.435% (+/- 0.0.1579%), and mutant hearts = 0.4885% (+/- 0.1722%). Three
hearts were examined per genotype, and three sections were analysed for each heart. There is no significant difference in apoptosis between the two
genotypes (unpaired 2-tailed Mann-Whitney U-test, p = 0.9292). Error bars in G and J represent standard error of the mean. Scale bars: A-F = 25 μm,
H-I = 50 μm.
https://doi.org/10.1371/journal.pgen.1007068.g012
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of TGFβ and PDGF inputs to mediate epicardial cellular changes associated with EMT
[70]. The NF-κB component p65 is expressed in the mouse epicardium during EMT [70].
We examined p65 expression at E14.5 in heterozygote control and Myh10Δ homozygous
mutant hearts (Fig 13J–13K) and calculated the ratio of epicardial staining intensity com-
pared to myocardial staining intensity. We found a statistically significant reduction in the
ratio in Myh10Δ mutant embryos, indicating reduced p65 expression in the mutant epicar-
dium (Fig 13L). Together, this evidence is highly suggestive of epicardial EMT dysregula-
tion specifically in the mutant epicardium. This result suggests an important role for
NMHC IIB in the promotion or execution of EMT, via NF-κB signaling, that to our knowl-
edge has not been reported previously.
Discussion
The present study demonstrates a requirement for NMHC IIB during the formation of the
mammalian coronary vasculature. Here, we report the characterisation of a mutant mouse
line, generated from a balancer chromosome ENU mutagenesis screen [19], that displays
embryonic hydrocephalus and cardiac defects. The EHC point mutation in Myh10 results in a
global loss of NMIIB function, as confirmed by genetic complementation of the EHC allele in
trans to the Myh10Δ allele. Notably, the Myh10 gene is located approximately 1 Mb outside the
Trp53 endpoint of the balancer chromosome interval [19]. In breeding the EHC mutants we
have only had 1 animal out of more than 1180 in total that showed recombination between the
Myh10 mutation and the balancer chromosome end point, indicating that the balancer chro-
mosome can be used to maintain balanced heterozygous stocks for embryonic lethal mutations
in genes located outside the balancer interval.
Our studies of the EHC mouse have made advances in understanding the essential role
undertaken by NMHC IIB during cardiogenesis. The EHC mutant coronary vessel abnormali-
ties are markedly similar to phenotypic observations of mice in which the epicardium has been
specifically disrupted [29, 31, 63], and are consistent with a primary defect in epicardial cell
function. We have shown that EHC mutant epicardial cells have a highly perturbed morphol-
ogy, impaired epicardial EMT, and disrupted subepicardial ECM composition, in addition to
reduced migration of EPDCs into the myocardium. The absence of mature coronary vessels in
EHC mutants suggests that in vivo these dysfunctional EPDCs are incapable of contributing to
the vascular network. A complementary study has demonstrated that coronary vessel develop-
ment is impaired when Myh10 is deleted specifically in the epicardium [53], consistent with
our conclusion that epicardial defects underpin disrupted coronary vessel development in
EHC mutant mice.
Fig 13. EHC epicardial cells show defects in EMT. A-B: EHC Heterozygous and C-D: EHC homozygous mutant E14.5 heart cryo-
sections were stained for the proliferation marker, PHH3 (green). Proliferating epicardial cells are indicated by arrowheads. The dashed
line indicates the boundary between the epicardium and myocardium. Cell nuclei were stained with DAPI (blue). E: Graph comparing the
proportions of proliferating cells (as a percentage of total cells) in both the epicardium and myocardium between controls and homozygous
mutants. Average proportion of proliferating cells in control = 4.953% (+/- 0.9674%) and EHC mutant epicardium = 14.17% (+/- 1.356%)
(unpaired 2-tailed t-test, p = <0.0001). Average proportion of proliferating cells in control = 16.70% (+/- 1.348%), and mutant myocardium =
14.09% (+/- 1.275%) (unpaired 2-tailed t-test, p = 0.1684). Error bars represent standard error of the mean. F-I: Localisation of the EMT
marker, Snail in the control and mutant epicardium (arrowheads). Cell nuclei are indicated by DAPI staining (blue). The EHC epicardium
shows a reduction in the number of cells in which EMT is activated. J: p65 immunofluorescence (green) in Myh10Δ heterozygous heart
showing expression in the epicardium (arrow). Nuclei are labeled with DAPI (blue). K: p65 immunofluorescence (green) in Myh10Δ
homozygous mutant heart showing diminished immunoreactivity in the epicardium (arrow). L: Quantification of p65 immunofluorescence
intensity in the epicardium relative to the myocardium. Genotypes are labeled on the graph. A statistically significant reduction in p65
epicardial expression is seen in Myh10Δ homozygous mutants (t-test, p = 0.003). Error bars represent standard deviation. Images were
analysed following the same methodology as reported for Fig 11D. Scale bars: A-D = 100μm, F-I = 50μm, J-K = 15 μm. Abbreviations: Wt1:
Wilms tumour 1, PHH3: phosphohistone H3.
https://doi.org/10.1371/journal.pgen.1007068.g013
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NMHC IIB plays a key role in a broad variety of fundamental cellular processes [20, 21].
Similarly, the defects we have documented encompass a range of physiological events, includ-
ing, but not limited to: cell migration, adhesion, proliferation and apoptosis. Our finding that
EHC mutants display defects in epicardial EMT is of particular interest, as other fundamental
developmental processes that depend upon the correct initiation and execution of EMT (e.g.
gastrulation, craniofacial development) occur in the EHC embryo. Indeed, formation of the
atrioventricular valves, a process dependent upon endocardial cushion EMT [13], is evident in
EHC mutant hearts (S5 Fig). We have demonstrated that NMHC IIB is the predominant
NMHC II isoform in epicardial cells both in vivo and in vitro, and that NMHC IIB is localised
to distinct subcellular regions (in agreement with the findings of Lo et al., [28], and Ma et al.,
[53]). Therefore, it may be hypothesised that NMHC IIB plays critical roles in epicardial and
cardiac development, which cannot be replaced by other NMHC II isoforms when NMHC IIB
function is globally ablated. The observation that loss of NMHC IIB leads to decreased expres-
sion of NMIIA presents the possibility of altered transcriptional regulation in EHC mutants,
which needs to be further explored to understand the roles of NMIIB in epicardial cell func-
tion, and embryonic development as a whole. Notably, unlike NMHC IIA or IIC, NMHC IIB
displays cell type and cell-cycle specific mechanosenstivity [71], which may be specifically
altered in mutant epicardial cells during development.
The myocardium also plays a role in epicardial cell behaviour, through the secretion of
paracrine signalling molecules which traverse the subepicardial ECM and communicate with
the epicardium to orchestrate correct epicardial function [13, 15, 50, 60]. The requirement for
NMHC IIB in myocardial development is well documented, with previous reports observing
myocardial disorganisation, cardiomyocyte cytokinesis defects, and a reduction of the myocyte
population in NMHC IIB null hearts [23, 33, 36, 37]. However, cardiomyocyte-specific Myh10
ablated mice are viable, and importantly, demonstrate a reduced instance of VSD and the com-
plete absence of DORV [35]. Here we report that NMHC IIB is not required within the cardio-
myocyte population for coronary vessel development. This finding suggests that the severe
morphological defects present in NMHC IIB null hearts are caused by loss of NMHC IIB from
other cardiac cell populations. It has recently been demonstrated that epicardial-specific dele-
tion of Myh10 does impair coronary vessel development [53], although the reported defects
are not as severe as we have documented here for the EHC mutant, EHC/Myh10Δ compound
heterozygote, or Myh10Δ homozygous mutant embryos. Further investigation is required to
determine if these phenotypic differences are due to differences in assays used or due to
requirements for NMHC IIB in multiple cell types during coronary vessel development.
NMHC IIB has been directly shown to be important in cell migration as a key component
of the actin-myosin cytoskeletal machinery [20, 21, 28, 36]. Our use of the epicardial cell cul-
ture model shows that the migration of EHC epicardial cells progresses unimpeded in vitro,
both in the context of epicardial cell outgrowth from embryonic heart explants, and in a
wound-healing assay. Moreover, cultured primary epicardial cells have been previously shown
to express Snail [72], indicating that the process of epicardial cell migration from explant heart
tissue in vitro involves EMT activation. A key difference between the explant model and the
EHC mutant is the context of the extracellular environment. We performed our explant assays
on gelatin-coated plates, and it has been demonstrated that the provision of exogenous ECM
substrate can compensate for migration defects in cells with ECM production deficiencies
[73]. It is known that the subepicardial ECM plays an important role in epicardial function, in
both the adhesion of the epicardial monolayer to the myocardium and in facilitating molecular
communication through the subepicardial space [13, 50, 60, 74]. During EMT, TGFβ signaling
(a key input for epicardial EMT [60]) is known to be affected by ECM substrate rigidity [75].
Additionally, alterations in cell tension, provoked by changes in the ECM, can disrupt nuclear
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architecture and chromatin structure, with subsequent effects on transcriptional regulation
[76]. Disruption of the subepicardial ECM as seen in EHC and Myh10Δ mutants may therefore
alter the ability of EHC EPDCs to migrate into the myocardium.
The detection of abnormalities in EMT signaling, indicated by increased epicardial cell pro-
liferation and reduced Snail expression in EHC mutants, is surprising, as NMHC IIB would be
expected to be a downstream effector of cell motility in EMT. Although EMT defects have
been detected in the epicardial-specific Myh10 knock out [53], comparison of the results of
that study with ours is complicated by the use of different assay methods and the potential for
requirements for NMHC IIB in non-epicardial cells to influence our findings. However, our
results suggest that the loss of NMHC IIB disrupts processes required for EMT signaling,
through the NF-κB pathway acting downstream of TGFβ and PDGF inputs [70]. PDGF is pro-
duced in the myocardium and serves as a paracrine signal to promote epicardial EMT [60].
Phenotypically, the epicardial cell morphology defects we note from EM studies are similar to
those reported for a PDGFRβ knock out [63]. Interestingly, it has previously been shown that
changes in ECM composition, particularly collagen, can alter PDGF responsive gene activation
during wound healing [77]. We have detected reduced p65 in Myh10Δ mutants, indicative of
impaired NF-κB pathway activation. Since NF-κB pathway activation occurs in response to
PDGFBB ligand inputs [70], we speculate that the observed alterations in the subepicardial
ECM of mutant embryos may impede PDGF signalling, which subsequently hinders NF-κB
pathway activation, thus contributing to epicardial EMT dysregulation in EHC and Myh10Δ
homozygous mutant embryos.
In summary we have demonstrated a requirement for NMHC IIB to generate the appropri-
ate cardiac extracellular matrix environment at the subepicardial space. We also demonstrate
that signals promoting epicardial cell EMT are deficient in EHC and Myh10Δ mutant embryos,
and that migration of EPDCs into the myocardium is impaired. Together, these data indicate
that the coronary defects observed in the EHC embryos are underpinned by compromised
epicardial function, and suggest that NMHC IIB plays a crucial role in normal epicardial biol-
ogy. Confirmation of our findings is provided from a recent study demonstrating that mice
with an epicardial-specific knock out of Myh10 display defects in coronary vessel development
[53]. Myh10 is a pleiotropic gene that performs multiple roles in different developmental pro-
cesses including tension generation [78], growth factor receptor internalisation [79], cell adhe-
sion [20], and extracellular matrix protein secretion [80]. Moreover, the different NMHC II
isoforms have functionally distinct roles [24]. Further investigation of the molecular functions
of NMHC IIB in the epicardium and other cardiac cell types may inform therapeutic strategies




Experiments using animals were performed in accordance with legislation in the UK Animals
(Scientific Procedures) Act of 1986 (PPL 70/8858 to Graham Morrissey). Experiments were
approved by the University of Manchester Animal Welfare and Ethical Review Body.
Mouse strains and genotyping
The l11Jus27 mouse line was generated from a balancer chromosome mutagenesis screen. The
two mutations carried in the l11Jus27 mouse line were maintained in trans to 129S5.Inv(11)
8BrdTrp53-Wnt3 [19]. Genomic DNA was prepared from ear punches of adult mice and yolk
sacs (<E11.5) or tails (E11.5) of embryos. Genotypes were determined by PCR analysis with
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microsatellite marker D11MIT327,D11MIT35,D11MIT31 or D11MIT322 to differentiate
between C57BL/6 (mutant) and 129S5 (wild type) strains of mice. Myh10tm7Rsad mice were
obtained from the MMRRC, and were crossed to Tg(Nes-cre)Wme mice to generate global dele-
tion of Myh10 exon 2. Tg(Myh6-cre)2182Mds/J mice were bred to Myh10tm7Rsad mice to generate
cardiomyocyte-specific deletion of Myh10 exon 2. Genotyping primers are listed in S1 Table.
PCR products were sequenced to confirm specificity of genotyping PCR reactions.
Meiotic mapping and NMHC IIB sequencing
For mutation mapping, mice were bred to 129S5 wild type mice. Animals inheriting the
l11Jus27 mutation but not the balancer chromosome were selected for further breeding.
l11Jus27 mice without the balancer were crossed to 129S5 wild type animals and progeny
examined for recombination events. Recombination events were identified using microsatel-
lite and SNP polymorphic markers between C57BL/6 and 129S5 mouse strains (primer
sequences in S1 Table). Recombinant mice were intercrossed to l11Jus27 mice and progeny
analysed. An absence of homozygous C57BL/6 pups indicated that the mutation was present
in the recombinant animal. A timed mating was performed to confirm the mutant phenotype.
Recombinant mouse 363, which only carried the ‘EHC’ point mutation, was bred with 129S5.
Inv(11)8BrdTrp53-Wnt3 to generate the EHC mouse line. The EHC point mutation was identified
by genomic sequencing of all annotated Myh10 exons (UCSC genome Browser mm9 assem-
bly). PCR amplification was performed on each exon, products precipitated, and cycle
sequenced using Big Dye v1.1 reaction mix (ABI) according to manufacturer’s instructions
(primer sequences in S1 Table).
Complementation assay
To confirm genomic deletion of Myh10 exon 2, PCR was performed for primers flanking exon
2 (Fig 6) and products were sequenced to confirm specificity to Myh10. Matings of Myh10Δ/
+ and EHC/+ male and female adult mice were set up and pregnancies were allowed to proceed
to term. Neonate litters were culled and tail biopsies from euthanised mice were used to geno-
type each animal for the Myh10Δ and EHC mutations. The observed genotypes were compared
to expected Mendelian ratios and data sets were analysed using a Chi-squared test with 2
degrees of freedom (http://graphpad.com/quickcalcs/chisquared1.cfm).
Embryo dissection and analysis
Mice were set up for timed matings and the morning of the vaginal plug was defined as day
E0.5. Mice were sacrificed according to Home Office Schedule 1 methods. Embryos were then
dissected from decidua at the desired time point and subsequently imaged in PBS using a
Leica MZ6 microscope and DFC420 camera.
Protein structure predictive modelling
The three dimensional structure of residues 1–815 of mouse NMHC IIB were predicted using
homology modelling. The sequences of mouse NMHC IIB and chicken smooth muscle myosin
were aligned using ClustalW [81], and structure predicted by Modeller [82] using the known
chicken myosin structure (PDB id 1BR1) [83] as a template. The sequence identity between
the two proteins was 83% over the aligned region. Twenty models were built, and the one with
the best score was used for further analysis.
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SDS-PAGE and Western blotting
Protein was extracted from E11.5 embryos by homogenisation in RIPA buffer. Protein concen-
trations were determined according to the manufacturer’s protocol (Biorad Protein Assay).
Protein lysate (30 μg) was loaded onto a 10% polyacrylamide gel and separated by electropho-
resis before being transferred to a PVDF membrane. Membranes were blocked overnight in
5% milk and incubated in anti-nonmuscle myosin II primary antibodies (NMIIA, Covance,
PRB-440P, NMIIB Covance, PRB-445P, NMIIC, Covance, PRB-444P; 1:1000) or anti-beta-
actin HRP conjugate (Sigma, A3854; 1:200,000) for 1 hour at room temperature. Membranes
were subsequently incubated in HRP conjugated donkey anti-rabbit secondary antibody
(Santa Cruz, SC-2313; 1:1000) for 1 hour at room temperature. Protein detection was per-
formed using the ECL Plus Western Blotting detection system (GE Healthcare) according to
manufacturer’s instructions.
Quantitative real-time PCR
RNA was prepared from E12.5 wild type, heterozygous and mutant embryos using Tri reagent
(Sigma). RNA (5 μg) was treated with RNase-free DNase 1 (Promega) and cDNA generated
using random primers (Promega) and Bioscript reverse transcriptase (Bioline). Primers for
Myh10 qPCR are listed in S1 Table.
Histology
Embryos were fixed in Bouin’s fixative or 4% paraformaldehyde (PFA), dehydrated and then
cleared in xylene or histoclear. Embryos were embedded in paraffin and sectioned at 7 μm.
After sectioning paraffin was removed from sections by washing 2 x 10 minutes in xylene or
histoclear. Sections were then rehydrated and stained in haemotoxylin and eosin or Alcian
blue and/or nuclear fast red before being mounted in depex mounting medium for analysis.
Immunohistochemistry and immunofluorescence
Embryos and embryonic hearts were fixed overnight in 4% PFA and stored in 70% ethanol.
For immunohistochemistry, whole hearts were incubated with primary antibodies anti-
PECAM-1 (BD Biosciences, 550274; 1:100) for 1 hour at room temperature. For immunohis-
tochemistry on tissue sections, samples were incubated in anti-smooth muscle alpha actin
(Sigma, A5228; 1:400) for 1 hour at room temperature. Staining was developed using the Vec-
tastain Elite ABC Kit (Vector, PK-6100) and visualised using the DAB substrate kit (Vector,
SK-4100). For immunofluorescence on tissue sections hearts were dehydrated, embedded in
paraffin and sectioned at 7 μm. Tissue sections were subjected to antigen retrieval by heating
in citrate buffer (DAKO, S1699) as per the manufacturer’s instructions. Tissue was blocked
prior to incubation in primary antibodies with either 10% (v/v) serum in PBS, or DAKO
serum free protein block (DAKO, X0909). Heart sections were stained with primary antibodies
directed against the following proteins: laminin (custom-made antibody, kind gift from Ray
Boot-Handford, University of Manchester; 1:400); fibronectin (Santa Cruz, SC-6952; 1:50 dilu-
tion), collagen 1 (Gentaur, OARA02579; 1:400), fibronectin (Santa Cruz, sc-6952, 1:50), p65
(Santa Cruz, SC-372; 1:200), cardiac Troponin T (Abcam, ab106076; 1:400), NMHC IIB (Euro-
gentec, PRB-445P-050; 1:400), Raldh2 (Abcam, ab75674: 1:200), SM22α (Abcam, ab14106;
1:250), endomucin (Santa Cruz, SC-65495; 1:50), sarcomeric alpha-actinin (Sigma, EA-53;
1:500), and beta-catenin (Sigma, C2206, 1:250) overnight at 4˚ C. Embryos were incubated in
species-specific fluorescent secondary antibodies (Jackson Immunochemicals or Invitrogen;
1:500 dilution) and slides mounted in DAPI mounting media (Vector).
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Blood cell peroxidase staining
Whole hearts were fixed for two hours at room temperature in 4% PFA. Hearts were washed
2X5 min in PBS, prior to incubation in the DAB substrate kit with added Nickel solution (Vec-
tor, SK-4100) according to manufacturer’s instructions.
Cryo-immunohistochemistry
E14.5 embryonic hearts were dissected into ice cold PBS, embedded in OCT (R.A. Lamb) and
snap frozen in liquid nitrogen. Cryosections (14 μm thick) were fixed in 4% PFA for 15 min-
utes, permeabilised in PBS + 0.1% (v/v) Triton X-100 for 15 minutes and subsequently blocked
with PBS + 1% (w/v) BSA + 10% (v/v) normal goat or horse serum (Vector) for 1 hour. Sec-
tions were then incubated with the following primary antibodies diluted in PBS + 0.1% (v/v)
Triton X-100 for 24 hours at 4˚C: rabbit polyclonal anti-mouse Wt-1 (Calbiochem, CA1026,
1:300), goat anti-Snail (Abcam, ab53519, 1:100), rabbit anti-PHH3 (Millipore, 06–570, 1:300),
anti-vimentin (Proteintech, 10366-1-AP, 1:50). Sections were then incubated with species-spe-
cific biotinylated secondary antibodies (Vector) at 1:500, for 2 hours, or FITC conjugated goat
anti-rabbit secondary antibody (Sigma, F9887, 1:160) (detection of PHH3). Sections were
incubated with Cy3 conjugated streptavidin (GE Healthcare, PA43001), diluted 1:3000 or
1:1000 (detection of Snail) for 30 minutes. Coverslips were mounted with Vectashield with
DAPI (Vector, H-1200) and sealed with nail varnish. Slides were stored in the dark at 4˚C and
imaged within 48 hours.
Epicardial cell culture
Cardiac fibroblast and cardiomyocyte cell populations were generated from E15.5 embryonic
hearts according to previously described protocols [38, 39]. For the generation of epicardial
cell cultures, embryonic hearts were dissected from E10.5–12.5 embryos and the atria and out-
flow tract were removed. Ventricular tissue was then carefully dissected into four pieces of
comparable size, and each piece was placed onto a coverslip pre-coated with 0.1% gelatin
(Sigma, G2500) (1 hour incubation at 37˚C) in a 24 well tissue culture plate (Corning).
Explants were cultured in 500μl DMEM (Sigma, D5796) supplemented with 15% (v/v) heat
inactivated FBS (Gibco, 10500064) and 1% (v/v) Penicillin/Streptomycin (Sigma, P0781).
Explants were incubated at 37˚C with 5% CO2 and the media was replaced every 3 days until
the cultures were required for experiments.
Immunocytochemistry
Epicardial cells cultured for 72 hours were washed with tissue culture grade PBS + MgCl2 and
CaCl2 (Sigma, D8662) and then fixed in 4% PFA for 10 minutes on an orbital shaker. The cov-
erslips were then washed and cell monolayers were permeabilised by incubating in PBS + 0.1%
(v/v) Triton X-100 for 15 minutes. Cultures were then blocked in either PBS + 10% (v/v) goat
serum, or PBS + 1% (w/v) BSA, for at least 1 hour before addition of relevant primary antibody
diluted in PBS + 0.1% (v/v) Triton X-100 for 1 hour: rabbit anti-ZO-1 (Invitrogen, 40–2300,
1:100), rabbit anti-Wt1 (1:300, SantaCruz, SC-192), goat anti-fibronectin (Santa Cruz, sc-6952,
1:100) or rabbit anti-NMHC IIB (Biolegend, PRB445P, 1:500). Unbound antibody was
removed by washing the cultures with PBS before addition of appropriate biotinylated second-
ary antibody (Vector) diluted 1:500 in PBS + 0.1% (v/v) Triton X-100 for 1 hour. For visualisa-
tion of fibronectin, cultures were incubated with FITC conjugated secondary antibody (Sigma,
F9887, 1:160) or developed using the Vectastain Elite ABC Kit (Vector, PK-6100) and visual-
ised using the DAB substrate kit (Vector, SK-4100) as per manufacturer’s instructions.
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Cultures were washed and then incubated in Cy5 conjugated streptavidin (GE Healthcare,
PA45001) diluted 1:500 in PBS + 0.1% (v/v) Triton X-100 for 30 minutes. Coverslips were
washed and then treated with 100nM rhodamine-phalloidin (Cytoskeleton, PHDR1) for 30
minutes to allow visualisation of the actin cytoskeleton. Following a final wash, coverslips were
mounted onto microscope slides using Vectashield with DAPI mounting media (Vector, H-
1200), and stored at 4˚C in the dark until imaging within 48 hours. The same protocol was
employed for immunofluorescence staining of NMHC IIB in cultured cardiac fibroblasts and
myocytes populations on gelatin coated glass coverslips.
TUNEL assay
Paraffin sections were rehydrated and subjected to TUNEL staining (Promega DeadEnd Fluo-
rometric TUNEL System, G3250) as per the manufacturer’s instructions.
Fluorescent microscopy image collection and analysis
Images were collected on an Olympus BX51 upright microscope and captured using a Cool-
snap ES camera (Photometrics) through MetaVue Software (Molecular Devices). Specific
band pass filter sets for DAPI, FITC, Cy3 and Cy5 were used to prevent bleed through from
one channel to the next. Images were then processed and analysed using ImageJ software
(Wayne Rasband, NIH, USA). (http://rsb.info.nih.gov/ij). IMARIS (Bitplane) 7.3.4 software
was used to analyse the fluorescence intensity in epicardial and myocardial regions for ECM
and p65 quantification. For each individual cell in the epicardial and myocardial layers, mean
fluorescence intensities (MFI), Alexa488, and Alexa 647 were measured in pixels. Twenty ran-
domly selected areas of the epicardium and myocardium were measured per tissue section.
Five sections per embryo, and three embryos of each genotype, were measured. Myocardial
measurements were taken from the compact myocardium as defined by morphology rather
than trabeculae or endocardium. Two-tailed student t-test was used to test the significance of
differences between two sets of data. Further details of data analysis techniques, statistical tests
and numbers of samples used are provided in figure legends.
Scratch wound assay
Epicardial cells were cultured from ventricular explants as described above. After 48 hours in
culture, explants were removed and the cell monolayer was briefly washed twice with complete
media and returned to the incubator for 24 hours. Cell monolayers were scratched using a P10
pipette tip, rinsed twice in complete media, and photographed at 10 minute intervals for 20
hours using an AS MDW live cell imaging system, maintained at 37˚C and 5% CO2. Ten cells
at the leading edge of the denuded area were tracked per field of view, using MTrackJ in Ima-
geJ. Total tracked cells = 240 control and 270 mutant. Cultures were generated from at least
four hearts for each genotype. Data sets for directional persistence and migration speed mea-
surements were subjected to Mann-Whitney U test to assess statistical significance.
Whole mount in situ hybridisation
Embryos were fixed overnight in 4% PFA and in situ hybridisation was performed as previ-
ously described [84, 85]. Tbx18 and Shox2 plasmids were obtained from A. Kispert (Institute
of Molecular Biology Hannover, Germany). Anti-sense probes were synthesized from linear
template DNA using RNA polymerase, digoxygenin nucleotide mix and transcription buffer
(Roche). RNA probes were purified by precipitation and added to hybridisation mix at a con-
centration of 0.5 μg/μl.
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Transmission electron microscopy
Samples were prepared for electron microscopy as described previously [86]. Sections (50–70
nm-thick) were generated using a Reichert-Jung Ultracut (Leica Microsystems, UK) and
stained using 2% uranyl acetate and 0.3% lead citrate. Sections were examined with an FEI
Tecnai 12 Biotwin transmission electron microscope. Images were recorded using a Gatan
Orius SC1000 camera (11 Mpixels, 4008 x 2672).
Supporting information
S1 Fig. Myh10Δ homozygous mutants do not synthesise full-length NMHC IIB protein
and exhibit embryonic lethality. A: Western blot analysis of E11.5 wild type, Myh10Δ hetero-
zygous control and Myh10Δ homozygous mutant heart protein extracts for NMHC IIB expres-
sion using a C-terminal antibody. NMHC IIB is abundant in controls but not detected in
homozygous mutant samples. B: Table showing expected Mendelian frequencies vs observed
frequencies of wild type, Myh10Δ heterozygous and Myh10Δ homozygous mutant progeny
from intercrossed Myh10Δ heterozygous animals (Chi squared test, p = 0.0035). C:
Table showing expected Mendelian frequencies vs observed frequencies of wild type, EHC/
+ or Myh10Δ/+ heterozygous and EHC/Myh10Δ compound heterozygous mutant progeny
from complementation test of intercrossed Myh10Δ/+ and EHC/+ heterozygous animals (Chi
squared test, p = 0.0278). The Myh10Δ allele does not rescue the EHC embryonic lethality phe-
notype, and therefore fails to complement the EHC allele.
(TIFF)
S2 Fig. Analysis of cardiac cell morphology in EHC mutants. Comparison of ventricular
cells in heterozygous control embryos at E12.5 (A) and EHC mutant hearts (B) at E12.5 reveals
mutant cells have large nuclei (B, arrows), consistent with prior descriptions of cytokinesis
defects in Myh10 knockout embryos. Immunofluorescent staining at E10.5 of heterozygous
control (C) and EHC mutant hearts (D). Cell-cell contacts are stained with β-catenin (green)
and myofibrils are stained with α-actinin (red), DAPI labels the nuclei (blue). Large nuclei are
also present in EHC mutant embryos at E10.5 (D, asterisks). EM imaging shows epicardial
cells in control embryos (E) and EHC mutant embryos (F-G). Multiple epicardial cells in EHC
mutants display abnormal morphology (F-G, white arrows), and large nuclei are present in
cells within the underlying myocardial tissue (F, black arrow). The percentage of epicardial
cells with abnormal morphology compared to total epicardial cell number was calculated from
images of 5 individual control embryos and 4 individual EHC mutant embryos. Overall there
was a statistically significant difference in the percentage of abnormal epicardial cells in control
embryos (11% abnormal) as compared to EHC mutants (71% abnormal; Fishers exact text
p<0.0001). Alcian blue staining indicates the presence of glycosaminoglycans in endocardial
cushion tissue in control littermate (H, J) and EHC mutant heart (I, K). The areas magnified in
panels J and K are indicated with boxes on panels H and I. Scale bars: A-D: 25 μm, E-F: 5 μm,
G = 17 μm, H-I: 1mm.
(TIF)
S3 Fig. Analysis of coronary vessel endothelial and smooth muscle cells in EHC/Myh10Δ
and Myh10Δ homozygous mutants. PECAM-1 staining at E16.5 reveals prominent vessels on
the dorsal surface of the Myh10Δ/+ control heart (A). The Myh10Δ/Δ (B) and Myh10Δ/EHC
(C) mutant hearts do not have surface vessels, but rather clusters of PECAM-1 immunoreac-
tive cells (arrows). Section immunohistochemistry for SMαA on D: EHC heterozygote, E: EHC
homozygous mutant, or F: EHC/Myh10Δ compound heterozygote at E16.5. Higher magnifica-
tions of the boxed areas in sections D-F reveals vessels ringed with SMαA cells in G: EHC
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heterozygote, but no such structures are present in H: EHC homozygous mutant or I: EHC/
Myh10Δ compound heterozygote. Similar results were observed for Myh10Δ homozygous
mutant embryos. J: High magnification view of PECAM-1 immunostaining on control heart
at E16.5 reveals large coronary vessels. K: EHC mutant heart at E16.5 immunostained for
PECAM-1 shows some evidence of a capillary network, along with surface blisters, but no
large vessels. Scale bars: A-C = 1mm, D-F and J-K = 0.25mm; G-I = 0.05mm. Abbreviations:
PECAM: platelet endothelial cell adhesion molecule-1, SMαA: smooth muscle alpha-actin, Δ:
Myh10Δ.
(TIF)
S4 Fig. Analysis of coronary vessel development in Myh10 cardiomyocyte-specific knock
out embryos. A-B: Ventral and dorsal views, respectively, of control littermate showing prom-
inent blood-filled coronary vessels (arrows) at dissection at E18.5. C-D: Ventral and dorsal
views, respectively, of Myh10 cardiomyocyte-specific knock out heart showing prominent
blood-filled coronary vessels (arrows) at dissection at E18.5. E: PECAM-1 staining reveals
prominent vessels (arrows) on the surface of the control heart at E16.5. F: PECAM-1 staining
reveals prominent vessels (arrows) on the surface of the Myh10 cardiomyocyte-specific knock
out heart at E16.5. Scale bars: 1 mm (A-F). Each pair of images is taken at the same magnifica-
tion. Genotypes are labeled on the image. Abbreviations: α-MHC: α-myosin heavy chain
encoded by Myh6, PECAM: platelet endothelial cell adhesion molecule-1.
(TIF)
S5 Fig. The atrioventricular valves are present in EHC mutant hearts. Nuclear fast red stain-
ing of E14.5 (A-B) and E16.5 (C-D) EHC heterozygote control and EHC homozygous mutant
hearts demonstrating the presence of both the mitral and tricuspid atrioventricular valve leaf-
lets (arrows). Scale bars: 1 mm.
(TIF)
S6 Fig. Analysis of fibronectin distribution in epicardial explant cultures. Immunohis-
tochemistry on epicardial explant cultures for control (A) and Myh10Δ homozygous mutant
(E) to detect fibronectin (arrows). Higher power images show a well-organised fibronectin
fibril network in control sample (B, arrows), but not in Myh10Δ homozygous mutant (F).
Immunofluorescence staining confirms that control samples have prominent localization of
fibronectin (C, green) while staining levels are reduced in mutants (G). Nuclei are visualised
with DAPI (blue). The underlying ECM in the explant culture dish was assayed for the pres-
ence of fibronectin following removal of explant cells with 20mM ammonium hydroxide,
revealing greater prominence of fibronectin in the control sample (D, arrows) as compared to
the Myh10Δ homozygous mutant sample (H, arrows). Explants were cultured on gelatin-
coated plates. Scale bars: A and E = 100 μm, B-C and F-G = 200 μm.
(TIF)
S7 Fig. Analysis of cell proliferation in control and Myh10Δ/Δ homozygous mutants at
E9.5. Phosphohistone H3 immunofluorescence (green) labels proliferating cells (arrows) in
control (A) and Myh10Δ homozygous mutant (B) cardiac sagittal sections at E9.5. No statisti-
cally significant difference (C) was detected in the percentage of proliferating cells in mutant
samples as compared to controls, (two-tailed t-test. p = 0.57). Three sections each from three
embryos of each genotype were counted. PHH3 stained cells in cardiac tissue only (identified
by morphology) were counted. DAPI positive nuclei (blue) in cardiac tissue only were counted
to determine total cell number in each sample. Abbreviations: PHH3: phosphohistone H3, Δ/Δ
= Myh10Δhomozygous mutant. Scale bars: 50 μm.
(TIF)
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S1 Movie. Movie of control epicardium scratch wound assay. Time-lapse microscopy imag-
ing of wound healing in control (+/+) epicardial cell cultures. A ‘denuded’ area was created by
scratching D3 epicardial cell culture monolayers with a P10 pipette tip. Point visiting was used
to image the same field of view at 10-minute intervals for a period of 20 hours. Ten cells per
field of view were tracked over the duration of the experiment using the MTrackJ plugin in
ImageJ (as indicated by multicoloured lines). Lines indicate the tracking of cells that were mea-
sured for speed and directional persistence.
(AVI)
S2 Movie. Movie of Myh10Δ/Δ mutant epicardium scratch wound assay. Lines indicate the
tracking of cells that were measured for speed and directional persistence, using the same
methodology as reported for S1 Movie.
(AVI)
S1 Table. Primer sequences used for genotyping and sequencing.
(DOCX)
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